This study looks at treating advanced lung cancer with two medicines: Interleukin-2 (IL-2), a protein that can help the immune system, and Pembrolizumab, a drug that helps the body fight cancer. In this study, patients with Stage IV non-small cell lung cancer (NSCLC) will be given both medicines to see if it helps their immune cells work better against cancer.
Key points to consider:
- This is an early phase 1 study, which means it is in the beginning stages of research.
- The treatment involves a combination of IL-2 and Pembrolizumab over several weeks with follow-up checks.
- Patients need to be 18 years or older and have not had previous treatments for their advanced lung cancer.
During the study, IL-2 will be given twice daily for three weeks, and Pembrolizumab will continue either every three or six weeks. After the initial treatment, there is a follow-up for 6 weeks. This study aims to see if this combination is safe and if it helps in treating lung cancer. Participants need to meet specific health criteria to join.
How understandable was the trial content above?
Hard to understand
Easy to understand